Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Accumulated Expenses: 2016-2020

Historic Other Accumulated Expenses for Akebia Therapeutics (AKBA) over the last 4 years, with Mar 2020 value amounting to $10.3 million.

  • Akebia Therapeutics' Other Accumulated Expenses fell 39.38% to $10.3 million in Q1 2020 from the same period last year, while for Mar 2020 it was $10.3 million, marking a year-over-year decrease of 39.38%. This contributed to the annual value of $9.5 million for FY2019, which is 20.97% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Other Accumulated Expenses of $10.3 million as of Q1 2020, which was up 7.48% from $9.5 million recorded in Q4 2019.
  • Over the past 5 years, Akebia Therapeutics' Other Accumulated Expenses peaked at $16.9 million during Q1 2019, and registered a low of $1.3 million during Q1 2016.
  • Its 3-year average for Other Accumulated Expenses is $9.3 million, with a median of $9.5 million in 2019.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 425.61% in 2019, then crashed by 39.38% in 2020.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Other Accumulated Expenses stood at $1.9 million in 2016, then climbed by 21.74% to $2.4 million in 2017, then spiked by 410.00% to $12.1 million in 2018, then dropped by 20.97% to $9.5 million in 2019, then tumbled by 39.38% to $10.3 million in 2020.
  • Its Other Accumulated Expenses stands at $10.3 million for Q1 2020, versus $9.5 million for Q4 2019 and $8.8 million for Q3 2019.